Merck Sharp + Dohme Corp.

Merch Sharp & Dohne Corp. Rahway

Harry R Chobanian

Barbara A Pio

Yan Guo

Michael W Miller

Christopher W Plummer

Ravi P Nargund

Dong Xiao

Haifeng Tang

Duane E DeMong

Linus S Lin

Ian M Bell

Alexander Pasternak

Jinlong Jiang

Zhicai Wu

Shawn J Stachel

James J Perkins

Jian Liu

Ping Liu

Mark E Layton

Shawn P Walsh

Helen Y Chen

Shuzhi Dong

Michael J Breslin

Tesfaye Biftu

William K Hagmann

Hubert B Josien

Bin Hu

Ashok Arasappan

Shuwen He

Jason M Cox

Christopher S Burgey

Dooseop Kim

Fa-Xiang Ding

Hong Liu

Robert J DeVita

William J Greenlee

Qun Dang

Kathleen M Rupprecht

Robert K Baker

Thomas J Greshock

Zhi-Cai Shi

Bowei Wang

Purakkattle J Biju

Ying-Duo Gao

Bing Li

Linda L Chang

Shouwu Miao

Timothy A Blizzard

Timothy Allen Blizzard

Christopher James Bungard

Deodial Guy Guiadeen

Marc D Chioda

Zhe Wu

Kristen L G Jones

Linda M Suen-Lai

Anthony T Ginnetti

Jessica Frie

Jinsong Hao

Cangming Yang

Candido Gude

Linda Brockunier

Zhengxia Chen

Brian T Campbell

Kevin Michael Belyk

Brendan M Crowley

Kenneth J Leavitt

Aurash Shahripour

Meibi Dai

Thomas A Bara

Mihir Mandal

Zhiyong Hu

Alejandro Crespo

Jason W Szewczyk

Vanessa L Rada

Rui Zhang

Matthew John Clements

Dann Parker

Ming Wang

Brian Cato

Ronald Dale Ferguson, Ii

Yang Yu

Zack Zhiqiang Guo

Mingxiang Cui

Karen M Marcantonio

Jeffrey W Schubert

James I Fells

Reynalda De Jesus

Reynalda K DeJesus

Duane Demong

Matthew J H Clements

Zaihong Zhang

Ying Lv

Lili Tian

Johnny Zhaoning Zhu

Minghai Fang

Deodial G Guiadeen

Michael Miller

Linda L Brockunier

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors

2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. 

2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I). 

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic heterocyclic compounds

Antidiabetic spirochroman compounds

Antidiabetic bicyclic compounds

[7,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassim channel

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

Growing community of inventors

Aberdeen, NJ, United States of America

Harry R Chobanian